M

Molecure SA
WSE:MOC

Watchlist Manager
Molecure SA
WSE:MOC
Watchlist
Price: 9.42 PLN -4.56% Market Closed
Market Cap: 158.6m PLN
Have any thoughts about
Molecure SA?
Write Note

Operating Margin
Molecure SA

-6 902.2%
Current
-1 713%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-6 902.2%
=
Operating Profit
-24.9m
/
Revenue
360.2k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
PL
Molecure SA
WSE:MOC
158.6m PLN
-6 902%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
756.2B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
351.2B USD
28%
US
Merck & Co Inc
NYSE:MRK
251.2B USD
34%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
21%
CH
Novartis AG
SIX:NOVN
171.5B CHF
31%
US
Pfizer Inc
NYSE:PFE
151.1B USD
22%
Country PL
Market Cap 158.6m PLN
Operating Margin
-6 902%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 756.2B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 351.2B USD
Operating Margin
28%
Country US
Market Cap 251.2B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 151.1B USD
Operating Margin
22%
No Stocks Found

Molecure SA
Glance View

Market Cap
158.6m PLN
Industry
Pharmaceuticals

Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.

MOC Intrinsic Value
21.41 PLN
Undervaluation 56%
Intrinsic Value
Price
M

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-6 902.2%
=
Operating Profit
-24.9m
/
Revenue
360.2k
What is the Operating Margin of Molecure SA?

Based on Molecure SA's most recent financial statements, the company has Operating Margin of -6 902.2%.